Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: June 2012

Lorcaserin (Arena/Eisai’s Belviq) approved by the FDA–the first new weight-loss drug in 13 years

Tweet  On June 27, 2012, Arena Pharmaceuticals and its commercialization pattern Eisai, Inc. (Woodcliff Lake, NJ) announced that the U.S. FDA had approved its antiobesity drug lorcaserin–the first drug for long-term weight loss to be approved in the U.S. in 13 years. Lorcaserin will be marketed under the trade name Belviq. The FDA approved lorcaserin…

Cancer immunotherapy: The star of the 2012 ASCO Annual Meeting

Tweet  The American Society of Clinical Oncology (ASCO) held its 2012 Annual Meeting on June 1-5, 2012. Arguably the highlight of the meeting was the June 2, 2012 presentation by Bristol-Myers Squibb (BMS) on its Phase 1 immunotherapeutic, anti-PD-1 (BMS-936558). The results of this study were also published ahead of print on June 2, in…

Developing resistance-free antibiotics by targeting quorum sensing

Tweet  Way back in May 2000, Decision Resources published my short report entitled “New approaches to small-molecule antibacterial drug discovery” as part of its Spectrum Life Sciences series. As might be expected, the report is now out of print. The report was a brief review of then-novel approaches to antibacterial drug discovery, in the face…